VIRALYTICS EVATAK ACTIVE AGAINST GASTRIC CANCERS IN MICE
December 21st 2008 23:46
Friday December 19, 2008
Daily news on ASX-listed biotechnology companies
* ASX UP, BIOTECHS DOWN: STARPHARMA UP 15%, SUNSHINE DOWN 29%
* BIOGUIDE BRIEF: METABOLIC SHAREHOLDERS GET IT RIGHT
* VIRALYTICS EVATAK ACTIVE AGAINST GASTRIC CANCERS IN MICE
* FLUOROTECHNICS WINS UK CUSTOMER
* TYRIAN TO SUPPLY DIAGNOSTIQS TO BAYER
* ANTEO APPOINTS JAMES HENDERSON CHAIRMAN
* AUSBIOTECH, ABN AMRO, BLUEPRINT ‘LATE STAGE’ SAN FRAN SHOW
To read all these articles in full, subscribe to Biotech Daily at the link above or at www.biotechdaily.com.au
VIRALYTICS
Viralytics says pre-clinical data shows anti-cancer activity of its oncolytic virus candidate, Evatak on cultures of gastric or stomach cancer.
Viralytics said the Evatak or Echovirus type 1 data would be published in the ‘Journal of Molecular Medicine’ by staff at the University of Newcastle on behalf of the company.
The company said the article, entitled, ‘Regional administration of oncolytic Echovirus 1 as a novel therapy for the peritoneal dissemination of gastric cancer’ described the positive oncolytic activity of Evatak on laboratory cell cultures of human gastric cancer and against gastric tumors grown in the peritoneal cavity, or the walls of the abdomen, of mice.
The company said it would post an electronic link on its website to the published article when it became available online.
Viralytics chief scientific officer Prof Darren Shafren said the data generated from pre-clinical trials of Evatak against human ovarian, prostate and gastric cancers “makes it a significant addition to our product pipeline, second in line to our lead product Cavatak”.
Earlier this year, Viralytics received a notice of allowance from the US Patent Office for its application covering the use of Echoviruses (including Evatak ) for the treatment of all cancers, including gastric cancer, bearing expression of the integrin alpha-2-Beta-1.
Evatak is the trade name for Viralytics’ proprietary formulation of the Echovirus Type 1.
The US National Cancer Institute predicts that 21,500 Americans will be diagnosed with gastric cancer in 2008 and 10,880 will die from the disease.
Treatment is dependent on stage and extent of the stomach cancer and options include surgery, chemotherapy and radiation therapy.
Viralytics fell 0.4 cents or 9.3 percent to 3.9 cents.
To read all these articles in full, subscribe to Biotech Daily at the link above or at www.biotechdaily.com.au
| 43 |
| Vote |
Add To: 
subscribe to this blog